Losartan Potassium shortage — US supply status & alternatives

Losartan Potassium

—

In supply · Australia

Loortan

In supply · 🇦🇺 Australia · short in🇺🇸 US🇨🇦 CA🇧🇪 BE

In supply in Australia

Reading today’s signals…

✓ Can I substitute?

Per normal rules

Confirm with prescriber

⇄ Best alternative

None listed

refer to prescriber

◷ Expected back

No estimate

No estimate provided

Product attributes reference data we hold

Active ingredient (INN)	Losartan Potassium
Brand names	Loortan
Therapeutic category	Auto-created by Federal Agency for Medicines and Health Products — PharmaStatus scraper

Controlled substance	No

Marketing-authorisation holders	ACCORD-UK LIMITED, TEVA UK LIMITED, SANDOZ LIMITED, ROSEMONT PHARMACEUTICALS LIMITED +3 more

Registrations on file	19

Patient information leaflet (PIL)	Not on file

Summary of product characteristics (SPC)	Not on file

Trade price 🇦🇺 Australia · awaiting price ingest

🇦🇺 AU

Ex-manufacturer

—

Dispensed (DPMQ)

—

Pack

—

Not yet captured for Australia

Official pricing isn’t on file for this market yet. PBS (Australia), NHS Drug Tariff (United Kingdom) and CMS NADAC (United States) feeds are prioritised; this panel populates automatically once the data lands.

Other markets

🇺🇸 US

US$0.03

Acquisition

Global API supply base 🇺🇸 FDA Drug Master Files · active Type II

26 API manufacturers

Manufacturers with an active Type II Drug Master File — i.e. cleared to supply this active ingredient into the US market. A proxy for how concentrated the global manufacturing base is.

Low concentration risk

Micro Labs LTDIol Chemicals And Pharmaceuticals LTDViyash Life Sciences Private LTDApitoria Pharma Private LTDMsn Life Sciences Private LTDAurore Life Sciences Private LTD+20 more

Manufacturing countries: India, China · Source: FDA List of Drug Master Files

Recalls official enforcement reports

🇺🇸

LOSARTAN POTASSIUM

Strides Pharma Inc. · June 2023

Class IIdetails ↗

🇺🇸

LOSARTAN POTASSIUM

PD-Rx Pharmaceuticals, Inc. · June 2022

Class IIdetails ↗

🇺🇸

LOSARTAN POTASSIUM

PD-Rx Pharmaceuticals, Inc. · June 2022

Class IIdetails ↗

🇺🇸

LOSARTAN POTASSIUM

PD-Rx Pharmaceuticals, Inc. · June 2022

Class IIdetails ↗

🇺🇸

LOSARTAN POTASSIUM

Strides Pharma Inc. · May 2022

Class IIdetails ↗

🇺🇸

LOSARTAN POTASSIUM

Strides Pharma Inc. · May 2022

Class IIdetails ↗

Registration recordmarketing-authorisation holders

Registrations & marketing-authorisation holders19 registrations · 7 MA holders

Product	Strength	Form	Market	MA holder	Status
Losartan Potassium/Hydrochlorothiazide 50/	12.5MG	tablet	🇬🇧 GB	ACCORD-UK LIMITED	Active
Losartan Potassium/Hydrochlorothiazide 100/	25MG	tablet	🇬🇧 GB	ACCORD-UK LIMITED	Active
Losartan Potassium/Hydrochlorothiazide	100MG	tablet	🇬🇧 GB	ACCORD-UK LIMITED	Active
LOSARTAN POTASSIUM 25MG FILM-COATED TABLETS	25MG	tablet	🇬🇧 GB	TEVA UK LIMITED	Active
LOSARTAN POTASSIUM 50 MG FILM-COATED TABLETS	50 MG	tablet	🇬🇧 GB	TEVA UK LIMITED	Active
LOSARTAN POTASSIUM 100MG FILM-COATED TABLETS	100MG	tablet	🇬🇧 GB	TEVA UK LIMITED	Active
Losartan Potassium/Hydrochlorothiazide	100 MG	tablet	🇬🇧 GB	SANDOZ LIMITED	Active
LOSARTAN POTASSIUM 10MG/ML ORAL SOLUTION	10MG	solution	🇬🇧 GB	ROSEMONT PHARMACEUTICALS LIMITED	Active
Losartan Potassium/Hydrochlorothiazide	50MG	tablet	🇬🇧 GB	KRKA, TOVARNA ZDRAVIL, D.D., NOVO MESTO	Active
LOSARTAN POTASSIUM 12.5 MG FILM-COATED TABLETS	12.5 MG	tablet	🇬🇧 GB	KRKA, TOVARNA ZDRAVIL, D.D., NOVO MESTO	Active
LOSARTAN POTASSIUM 25 MG FILM-COATED TABLETS	25 MG	tablet	🇬🇧 GB	KRKA, TOVARNA ZDRAVIL, D.D., NOVO MESTO	Active
LOSARTAN POTASSIUM 100 MG FILM-COATED TABLETS	100 MG	tablet	🇬🇧 GB	KRKA, TOVARNA ZDRAVIL, D.D., NOVO MESTO	Active
Losartan Potassium/Hydrochlorothiazide 100/	12.5MG	tablet	🇬🇧 GB	KRKA, TOVARNA ZDRAVIL, D.D., NOVO MESTO	Active
Losartan Potassium/Hydrochlorothiazide	50 MG	tablet	🇬🇧 GB	SANDOZ LIMITED	Active
Losartan Potassium / Hydrochlorothiazide	100 MG	tablet	🇬🇧 GB	SANDOZ LIMITED	Active

+4 more registrations on file

For health-professional reference only. Mederti aggregates shortage and substitution information from official regulatory sources. It is not clinical advice and data may be incomplete or delayed. Confirm any substitution or supply decision against the primary regulator source, the prescriber, and current clinical references (e.g. AMH) before acting. Terms.